Sophie E Vollenbrock1,2, Jolanda M van Dieren3, Francine E M Voncken4, Sietze T van Turenhout3, Liudmila L Kodach5, Koen J Hartemink6, Johanna W van Sandick6, Berthe M P Aleman4, Regina G H Beets-Tan7,8, Annemarieke Bartels-Rutten7. 1. Department of Radiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. s.vollenbrock@nki.nl. 2. GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. s.vollenbrock@nki.nl. 3. Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 4. Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 5. Department of Pathology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 6. Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 7. Department of Radiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. 8. GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Abstract
OBJECTIVES: In order to select oesophageal cancer patients after neoadjuvant chemoradiotherapy (nCRT) for organ-preserving treatment instead of surgery, a high diagnostic accuracy is required. The aim of this study was to evaluate whether MRI had additional value to gastroscopy with biopsies and endosonographic ultrasound (EUS) with fine needle aspiration (FNA) for the detection of residual tumour after nCRT. METHODS: Twenty-two patients with oesophageal cancer eligible for nCRT followed by oesophagectomy were prospectively included. All patients underwent (T2- and diffusion-weighted) MRI and gastroscopy+EUS before and after nCRT. Histopathology after oesophagectomy was the reference standard with pathological complete response (pCR) defined as ypT0N0. Diagnostic performance regarding the detection of residual tumour was calculated for gastroscopic biopsies and for EUS-FNA without and with MRI. RESULTS: Nineteen of the 22 patients (86%) did not achieve pCR after nCRT (7 ypT+N+, 11 ypT+N0, 1 ypT0N+). Biopsies detected residual tumour in 6 of 18 ypT+ patients. After adding MRI, 16 of 18 residual tumours were assessed correctly. EUS-FNA detected 3 out of 8 ypN+ patients, while MRI did not improve detection. Overall, adding MRI improved sensitivity for detection of residual tumour to 89% (17 of 19) from 47% (9 of 19) with endoscopic biopsies and EUS-FNA only. CONCLUSION: In this small study, the detection of residual tumour after nCRT in oesophageal cancer patients was improved by the addition of MRI to gastroscopy and EUS. KEY POINTS: • In this small study, the detection of residual tumour after neoadjuvant chemoradiotherapy in oesophageal cancer patients was improved by adding MRI including diffusion-weighted images to gastroscopy and endosonographic ultrasound. • With the addition of MRI assessment to gastroscopy and endosonographic ultrasound, the considerable risk of missing residual tumours decreased from 53 to 11%, while the pitfall was overstaging in one out of three complete responders.
OBJECTIVES: In order to select oesophageal cancerpatients after neoadjuvant chemoradiotherapy (nCRT) for organ-preserving treatment instead of surgery, a high diagnostic accuracy is required. The aim of this study was to evaluate whether MRI had additional value to gastroscopy with biopsies and endosonographic ultrasound (EUS) with fine needle aspiration (FNA) for the detection of residual tumour after nCRT. METHODS: Twenty-two patients with oesophageal cancer eligible for nCRT followed by oesophagectomy were prospectively included. All patients underwent (T2- and diffusion-weighted) MRI and gastroscopy+EUS before and after nCRT. Histopathology after oesophagectomy was the reference standard with pathological complete response (pCR) defined as ypT0N0. Diagnostic performance regarding the detection of residual tumour was calculated for gastroscopic biopsies and for EUS-FNA without and with MRI. RESULTS: Nineteen of the 22 patients (86%) did not achieve pCR after nCRT (7 ypT+N+, 11 ypT+N0, 1 ypT0N+). Biopsies detected residual tumour in 6 of 18 ypT+ patients. After adding MRI, 16 of 18 residual tumours were assessed correctly. EUS-FNA detected 3 out of 8 ypN+ patients, while MRI did not improve detection. Overall, adding MRI improved sensitivity for detection of residual tumour to 89% (17 of 19) from 47% (9 of 19) with endoscopic biopsies and EUS-FNA only. CONCLUSION: In this small study, the detection of residual tumour after nCRT in oesophageal cancerpatients was improved by the addition of MRI to gastroscopy and EUS. KEY POINTS: • In this small study, the detection of residual tumour after neoadjuvant chemoradiotherapy in oesophageal cancerpatients was improved by adding MRI including diffusion-weighted images to gastroscopy and endosonographic ultrasound. • With the addition of MRI assessment to gastroscopy and endosonographic ultrasound, the considerable risk of missing residual tumours decreased from 53 to 11%, while the pitfall was overstaging in one out of three complete responders.
Entities:
Keywords:
Gastroscopy; Magnetic resonance imaging; Oesophageal neoplasms
Authors: Ruben D van der Bogt; Bo J Noordman; Kausilia K Krishnadath; Carlijn A M Roumans; Erik J Schoon; Liekele E Oostenbrug; Peter D Siersema; Frank P Vleggaar; J Jan B van Lanschot; Manon C W Spaander Journal: Endoscopy Date: 2018-11-29 Impact factor: 10.093
Authors: Didi J J M de Gouw; Bastiaan R Klarenbeek; Mitchell Driessen; Stefan A W Bouwense; Frans van Workum; Jurgen J Fütterer; Maroeska M Rovers; Richard P G Ten Broek; Camiel Rosman Journal: J Thorac Oncol Date: 2019-04-15 Impact factor: 15.609
Authors: Joel Shapiro; Fiebo J W ten Kate; Pieter van Hagen; Katharina Biermann; Bas P L Wijnhoven; J Jan B van Lanschot Journal: Ann Surg Date: 2013-11 Impact factor: 12.969
Authors: A M Mandard; F Dalibard; J C Mandard; J Marnay; M Henry-Amar; J F Petiot; A Roussel; J H Jacob; P Segol; G Samama Journal: Cancer Date: 1994-06-01 Impact factor: 6.860
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Bo Jan Noordman; Bas P L Wijnhoven; Sjoerd M Lagarde; Jurjen J Boonstra; Peter Paul L O Coene; Jan Willem T Dekker; Michael Doukas; Ate van der Gaast; Joos Heisterkamp; Ewout A Kouwenhoven; Grard A P Nieuwenhuijzen; Jean-Pierre E N Pierie; Camiel Rosman; Johanna W van Sandick; Maurice J C van der Sangen; Meindert N Sosef; Manon C W Spaander; Roelf Valkema; Edwin S van der Zaag; Ewout W Steyerberg; J Jan B van Lanschot Journal: BMC Cancer Date: 2018-02-06 Impact factor: 4.430